| 靶向给药系统及其在眼科的应用 |
|
| http://www.cnophol.com 2008-1-9 15:52:22 中华眼科在线 |
［9］ 孙岩秀，李筱荣．5氟尿嘧啶抑制兔晶状体上皮细胞增殖及眼内毒性的研究［J］．眼科研究，2000，18（3）：224226．
［10］ Suresh KP, Beatrice C, David JA, et al. Intracapsular ring sustained 5fluorouracil delivery system for the prevention of posterior capsule opacification in rabbits: a histological study［J］. J Cataract Refract Surg, 2002, 28(1):139148.
［11］ 刘晓燕，常津，郭艳霜，等．靶向抑制晶状体上皮细胞增殖的载药毫微球的研究［J］．中国生物医学工程学报，2004，23（6）：583588．
［12］ Hiroshi K, Hideya K, Tsrtomu Y, et al. Monoclonal antibodymediated drug targeting to choroidal neovascularization in the rat［J］. Invest Ophthalmol Vis Sci, 2001, 42:26642672.
［13］ Reem ZR, Yoshiko T, Makhluf JH, et al. Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor2［J］. Arch Ophthalmol, 2004, 122:10021011.
［14］ 谢云飞．配体-受体系统介导的药物靶向性研究进展［J］．药物生物技术，2004，11（2）:130134．
［15］ Kabbinavar F, Hurwitz H I, Fehrenbacher L, et al. Phase II,randomized trial comparing bevacizumab plus fluorouracil(FU)/leucovorin(LV) with FU/LV alone in patients with metastatic colorectal cancer［J］. J Clin Oncol, 2003, 21(1):6065.
［16］ Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer［J］. N Engl J Med, 2003, 349(5):427.
［17］ Hess C, Vuong V, Hegyi I, et al. Effect of VEGF receptor inhibitor PTK 787/ZK 222584［correction of ZK 222548］ combined with ionizing radiation on endothelial cells and tumour growth［J］. Br J Cancer, 2001, 85(12):2010.
［18］ Giles FJ, Cooper MA, Silverman L, et al. Phase II study of SU5416A small molecule, vcascular endothelial growth factor tyrosinekinase receptor inhibitorin patients with refractory myeloproliferative diseases［J］. Cancer, 2003,97(8):1920.
［19］ Patton TF, Robinson JR. Quantitative precorneal disposition of topically applied pilocarpine nitrate in rabbit eyes［J］. J Pharm Sci, 1976, 65:12951301.
［20］ Pilar C, Charles T, Maria J, et al. Study of the mechanism of interaction of poly(caprolactone) nanocapsules with the cornea by confocal laser scanning microscopy［J］. Int J Pharma, 1994, 103:283291.
［21］ Bourlais CL, Acar L, Zia H, et al. Ophthalmic drug delivery system recent advances［J］. Prog Retin Eye Res, 1998, 17:3358.
［22］ De Campos AM, Sanchez A, Alonso MJ. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface［J］. Int J Pharm, 2001, 224:159168.
［23］ Bourges JL, Gautier SE, Delie F, et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles［J］. Invest Ophthalmol Vis Sci, 2003, 44：35623569.
［24］ Zimmer A. Antisence oligonucleotides delivery with polyhexylcyanoacylate nanopareicles as carriers［J］. Method, 1999, 18:286295.
［25］ Lambert G, Fattal E, Pinto AH, et al. Poliisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides［J］. Pharm Res, 2000, 17:707714.
［26］ Reynolds AR, Moein MS, Hodivala DK. Nanoparticlemediated gene delivery to tumor neovasulature［J］. Trends Mol Med, 2003, 99(1):24.上一页 [1] [2] [3] [4] [5] [6] |
| （来源：山东大学耳鼻喉眼学报）（责编：xhhdm） |
|
      |
| 下一条： 超声乳化术中角膜内皮细胞损伤的多因素分析 |
 |
更多关于（眼科,眼睛,眼科疾病,眼科临床,眼部肿瘤,眼科应用,黄斑变性,）的信息 |
|
|
 热门图文 |
|
|
|
|
|
| 健康新看点 |
|
|
| 健康多视点 |
|
|
| 图话健康 |
|
|
|
